What’s In This Video Webinar
Combination products require the delivery of pharmaceutical actives at precise levels determined by the intended therapeutic dose and established toxicity limits. Both device design and polymer chemistry in are essential to ensuring the intended delivery is achieved.
Thermoplastic polyurethanes (TPUs) offer customizable, segmented polymer chemistry that can be tailored to a specific loading/release target. In this study, Lubrizol’s Pathway™ TPUs were used to develop a data-driven model that predicts drug delivery based on API-polymer interactions and elution rates, potentially accelerating formulation development.
View The Video Webinar
What’s In This Video Webinar
Taking a drug product from clinical to commercial-scale production is a complex process with numerous variables to consider. Finding an appropriately sized CDMO to help you go to market can be difficult, especially when manufacturing capacity shortages are common and many CMOs focus on more established or high-volume products. Companies who are developing sterile products, such as injectable or ophthalmic dosage forms, must also ensure manufacturing sites are prepared for the challenges of aseptic manufacturing.
To find the right partner, you must know what to look for in a CDMO. In this webinar from Lubrizol Life Science Health (LLS Health), we will describe how LLS Health’s CDMO Division is meeting the need for commercial aseptic manufacturing capacity and explore key considerations when selecting a CDMO for commercial supply, including:
- The importance of flexibility and transparency
- Selecting the “right-sized” CDMO
- Strategies for reducing risk
- Best practices for project management
- Streamlining projects with a full-service CDMO
View The Video Webinar
What’s In This Video Webinar
Delivery of therapeutics to the human eye is one of the most interesting—but challenging—endeavors a formulator can take on. The anatomy and chemical composition of the eye makes it highly resistant to pharmaceutical penetration. Successfully circumventing these protective barriers requires intimate knowledge of ocular delivery as well as specialized development and manufacturing expertise.
This webcast explores solutions to some of today’s most challenging issues in ophthalmic drug delivery including a selection of dosage form, options for increasing bioavailability, improving drug stability, properly handling highly potent APIs, overcoming patient compliance issues, and meeting the sterility critical quality attribute.
View The Video Webinar
What’s In This Video Webinar
Nanotechnology, the manipulation of materials at the nanometer length scale, sounds like daunting sci-fi, but in practice provides the pharmaceutical product developer with a host of options to protect a labile drug molecule, improve the bioavailability of a drug, target a drug to specific tissues or cells, or simply offer a reformulation option to manage the lifecycle of an existing product.
This webcast explores the most common nanotechnologies practices for pharmaceutical formulation development, the pros and cons of each approach, which types of molecules can be incorporated and how, specific manufacturing equipment, characterization, and regulatory considerations.
View The Video Webinar
What’s In This Video Webinar
A growing number of APIs suffer from poor water solubility, low bioavailability, and insufficient stability. As more BCS class II–IV compounds enter the drug development pipeline, formulators must look to advanced drug delivery systems to achieve a desired therapeutic effect and protect APIs from degradation. Long-acting dosage forms such as microparticle depot injections and implantable systems—both biodegradable and biodurable—offer tunable designs that help overcome these challenges. However, successful development and optimization of these complex drug products require specialized knowledge, equipment, and facilities to properly execute.
This webinar explores key considerations in developing long-acting drug products, including a comparison of design options, polymers, and manufacturing methods for both depots and implants. Experts investigate some of the common challenges in these areas and explain how long-acting dosage forms are characterized by real-world case studies.